Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06039826 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT06039826: Completed Phase 1 study, sponsored by Eli Lilly and Company.
NCT06039826 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 46 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (23% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06039826, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
The main purpose of this study is to determine the effect of LY3437943 when administered subcutaneously on the levels of combined oral contraceptive (COC) ethinyl estradiol and drospirenone in the blood stream in postmenopausal female participants who are overweight or obese. The safety and tolerability of LY3437943 when administered with COC will also be evaluated. This study will last up to approximately 29 weeks for each participant.
Primary Outcome
PK: AUC0-24 of Ethinyl Estradiol
Interventions
- DRUG LY3437943
- DRUG Drospirenone
- DRUG Ethinyl Estradiol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2023-09-12 |
| Est. Completion | 2024-07-11 |
| Phase | Phase 1 |
What the finished NCT06039826 record still lists
NCT06039826 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (23% lower).
The record links to 0 conditions, and to 3 interventions - of which LY3437943 is the first listed.
NCT06039826 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06039826 about?
NCT06039826 is a clinical study titled "A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese". The main purpose of this study is to determine the effect of LY3437943 when administered subcutaneously on the levels of combined oral contraceptive (COC) ethinyl estradiol and drospirenone in the blood stream in postmenopausal female participants who are overweight or obese. The safety and tolerabi...
What is the current status of trial NCT06039826?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2023-09-12. Estimated completion is 2024-07-11.
What interventions are being tested in trial NCT06039826?
The interventions under investigation include: LY3437943 (DRUG), Drospirenone (DRUG), Ethinyl Estradiol (DRUG).
Who is sponsoring clinical trial NCT06039826?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06039826's enrollment target sits among peer trials
46 1058th of 2000 higher than 935 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI